3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
143
Carcinoma, Neuroendocrine
56
Thyroid Cancer, Papillary
54
Pheochromocytoma
50
Thyroid Neoplasms
41
Paraganglioma
41
Pituitary Neoplasms
37
Adrenocortical Carcinoma
31
Neoplasms
30
Multiple Endocrine Neoplasia Type 1
29
Gastro-enteropancreatic neuroendocrine tumor
29
Thyroid Carcinoma, Anaplastic
23
Small Cell Lung Carcinoma
21
Lung Neoplasms
21
Carcinoid Tumor
20
Sarcoma
19
Breast Neoplasms
19
Neoplasm Metastasis
18
Carcinoma, Non-Small-Cell Lung
18
Adenoma, Islet Cell
18
Melanoma
17
Carcinoma, Hepatocellular
17
Prostatic Neoplasms
15
Pancreatic Neoplasms
15
Ovarian Neoplasms
15
Neuroblastoma
15
Colorectal Neoplasms
15
Carcinoma, Renal Cell
15
Adrenal Gland Neoplasms
15
Adenocarcinoma, Follicular
15
Interventions
exemestane
1
Vildagliptin
1
Tamoxifen
1
Metformin
1
Letrozole
1
Fulvestrant
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperglycemia
×
Endocrine
×
1 year
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled